"NVIDIA has launched BioNeMo, a generative AI cloud service that speeds up drug discovery and research in the life sciences. The service allows researchers to fine-tune AI applications based on their own data and run AI models through web browsers or APIs. Amgen is already using BioNeMo to advance its research and development efforts. The service provides pretrained AI models for tasks such as protein structure prediction and molecule generation. It is being used by pharmaceutical companies and startups in their drug development workflows. NVIDIA has collaborated with Amgen, Evozyne, and Insilico Medicine to develop BioNeMo, which has shown promising results in various applications in biotechnology and pharmaceutical industries. The text also contains disclaimers, trademark information, and details about recent news and developments related to NVIDIA."